PT1069185E - Anticorpo humanizado contra factor tecidual (tf) humano e processo para construção de um anticorpo humanizado - Google Patents

Anticorpo humanizado contra factor tecidual (tf) humano e processo para construção de um anticorpo humanizado Download PDF

Info

Publication number
PT1069185E
PT1069185E PT99912098T PT99912098T PT1069185E PT 1069185 E PT1069185 E PT 1069185E PT 99912098 T PT99912098 T PT 99912098T PT 99912098 T PT99912098 T PT 99912098T PT 1069185 E PT1069185 E PT 1069185E
Authority
PT
Portugal
Prior art keywords
chain
humanized antibody
region
humanized
tissue factor
Prior art date
Application number
PT99912098T
Other languages
English (en)
Inventor
Koh Sato
Hideki Adachi
Naohiro Yabuta
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of PT1069185E publication Critical patent/PT1069185E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT99912098T 1998-04-03 1999-04-02 Anticorpo humanizado contra factor tecidual (tf) humano e processo para construção de um anticorpo humanizado PT1069185E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9185098 1998-04-03

Publications (1)

Publication Number Publication Date
PT1069185E true PT1069185E (pt) 2011-08-11

Family

ID=14038058

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99912098T PT1069185E (pt) 1998-04-03 1999-04-02 Anticorpo humanizado contra factor tecidual (tf) humano e processo para construção de um anticorpo humanizado

Country Status (19)

Country Link
US (2) US6677436B1 (pt)
EP (2) EP1069185B1 (pt)
JP (2) JP3998419B2 (pt)
KR (1) KR20010042435A (pt)
CN (1) CN1303431A (pt)
AT (1) ATE512225T1 (pt)
AU (1) AU752730B2 (pt)
BR (1) BR9909382A (pt)
CA (1) CA2325346A1 (pt)
DK (1) DK1069185T3 (pt)
ES (1) ES2364266T3 (pt)
HU (1) HUP0101160A2 (pt)
IL (1) IL138801A0 (pt)
NO (1) NO20004946L (pt)
PL (1) PL343322A1 (pt)
PT (1) PT1069185E (pt)
SK (1) SK14812000A3 (pt)
TR (2) TR200101541T2 (pt)
WO (1) WO1999051743A1 (pt)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU716282B2 (en) 1995-06-07 2000-02-24 Johnson & Johnson Research Pty. Limited CDR-grafted anti-tissue factor antibodies and methods of use thereof
US6703197B1 (en) * 1996-11-27 2004-03-09 Martinex R&D, Inc. Human methionine synthase: cloning, and methods for evaluating risk of neural tube defects, cardiovascular disease, and cancer
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) * 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US7764130B2 (en) * 1999-01-22 2010-07-27 Multigig Inc. Electronic circuitry
CZ20021035A3 (cs) * 1999-10-01 2002-08-14 Chugai Seiyaku Kabushiki Kaisha Prevence a léčba nemocí souvisejících s poruchami krevní sráľlivosti
DE19962583A1 (de) * 1999-12-23 2001-06-28 Mueller Hermelink Hans Konrad Antikörper gegen Plasmazellen
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
EP1263960A2 (en) * 2000-03-16 2002-12-11 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
US7332289B2 (en) 2001-03-09 2008-02-19 Chugai Seiyaku Kabushiki Kaisha Method of purifying protein
WO2002078738A1 (fr) * 2001-03-26 2002-10-10 Koji Suzuki Agents ameliorant la rheologie sanguine
EP1428537B1 (en) * 2001-08-29 2008-11-19 Chugai Seiyaku Kabushiki Kaisha Stabilized preparations containing antibody
WO2003029295A1 (en) * 2001-10-02 2003-04-10 Novo Nordisk A/S Human tissue factor antibodies
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
WO2003057881A1 (fr) * 2001-12-28 2003-07-17 Chugai Seiyaku Kabushiki Kaisha Procede de stabilisation d'une proteine
CA2483909A1 (en) * 2002-05-01 2003-11-13 Schering Aktiengesellschaft Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
GB0210783D0 (en) * 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
AU2003242430A1 (en) * 2002-05-23 2003-12-12 Chugai Seiyaku Kabushiki Kaisha Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation
EP1541165A4 (en) 2002-08-27 2009-06-24 Chugai Pharmaceutical Co Ltd METHOD FOR STABILIZING PROTEIN PREPARATION
EP3225625A1 (en) 2002-09-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Protein purification method
AU2003277832A1 (en) * 2002-10-31 2004-05-25 Novo Nordisk A/S Humanized tissue factor antibodies
US7223393B2 (en) * 2003-02-07 2007-05-29 Pdl Biopharma, Inc Amphiregulin antibodies and their use to treat cancer and psoriasis
US8765124B2 (en) 2003-02-28 2014-07-01 Chugai Seiyaku Kabushiki Kaisha Stabilized preparation containing protein
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
CA2527621A1 (en) * 2003-05-30 2004-12-23 Centocor, Inc. Method of inhibiting tumor growth with anti-tissue factor antibodies
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
WO2005004793A2 (en) * 2003-06-19 2005-01-20 Tanox Inc. Compositions and methods for treating coagulation related disorders
US20050106147A1 (en) * 2003-08-29 2005-05-19 Robert Jordan Method of promoting graft survival with anti-tissue factor antibodies
WO2005035753A1 (ja) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
JPWO2005035754A1 (ja) 2003-10-14 2006-12-21 中外製薬株式会社 機能蛋白質を代替する二種特異性抗体
EP2077282B1 (en) * 2003-11-05 2016-12-28 Roche Glycart AG Antigen binding molecules with increased Fc receptor binding affinity and effector function
US7910100B2 (en) 2004-10-01 2011-03-22 Max-Planck-Gesellschaft zur Forderung der Wissen Antibodies directed to the mammalian EAG1 ion channel protein
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
BRPI0608468A2 (pt) * 2005-03-25 2010-01-05 Glycart Biotechnology Ag moléculas de ligação a antìgeno direcionadas a mcsp e tendo afinidade de ligação a receptor de fc e função efetora aumentadas
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
DK2824183T3 (da) 2005-04-08 2020-09-28 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af bispecifikke antistoffer
MX2007013924A (es) * 2005-05-09 2008-01-28 Glycart Biotechnology Ag Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc.
EP1937720B1 (en) 2005-08-18 2014-04-09 Ramot at Tel-Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
SG192479A1 (en) * 2005-08-26 2013-08-30 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
WO2007074880A1 (ja) 2005-12-28 2007-07-05 Chugai Seiyaku Kabushiki Kaisha 抗体含有安定化製剤
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
CA2669330A1 (en) * 2006-11-15 2008-11-20 Functional Genetics, Inc. Methods and compositions for treating influenza
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
WO2008069999A2 (en) 2006-12-01 2008-06-12 Selexys Pharmaceuticals Corporation Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
CA3066453C (en) 2007-09-26 2022-01-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
ES2585480T3 (es) 2007-12-05 2016-10-06 Chugai Seiyaku Kabushiki Kaisha Anticuerpo anti-NR10 y uso del mismo
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP2271670B1 (en) * 2008-03-14 2014-09-03 Allergan, Inc. Immuno-based botulinum toxin serotype a activity assays
WO2009126920A2 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
US8187601B2 (en) * 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
CA2730201C (en) 2008-07-10 2019-02-05 Toray Industries, Inc. Anti-cd179b antibody
RU2498819C2 (ru) 2008-08-05 2013-11-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и профилактики злокачественных опухолей
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8927694B2 (en) * 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
UA109633C2 (uk) * 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
JP5780762B2 (ja) 2008-12-25 2015-09-16 国立大学法人大阪大学 抗ヒトインフルエンザウイルス・ヒト型抗体
TWI646193B (zh) 2009-03-19 2019-01-01 中外製藥股份有限公司 抗體恆定區域改變體
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
CA2761891A1 (en) 2009-05-15 2010-11-18 Chugai Seiyaku Kabushiki Kaisha Anti-axl antibody
US20120141501A1 (en) 2009-05-29 2012-06-07 Forerunner Pharma Research Co. Ltd Pharmaceutical Composition Containing Antagonist of EGF Family Ligand as Component
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
CN101717447B (zh) * 2009-12-17 2012-06-27 山西省生物研究所 一种抗人重组组织因子单克隆抗体的制备方法
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
US8937160B2 (en) 2010-02-04 2015-01-20 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
RU2603742C2 (ru) 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
CA2788547C (en) 2010-02-04 2018-06-05 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
CA2788715C (en) 2010-02-04 2021-06-08 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
AU2011211682B2 (en) 2010-02-04 2015-08-13 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
ES2647388T3 (es) 2010-06-15 2017-12-21 Genmab A/S Conjugados farmacológicos de anticuerpos humanos contra factor tisular
MX355060B (es) 2010-11-17 2018-04-03 Chugai Pharmaceutical Co Ltd Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
KR102147548B1 (ko) 2011-02-25 2020-08-24 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
US8722044B2 (en) 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
EP2735315B1 (en) 2011-07-19 2019-10-02 Chugai Seiyaku Kabushiki Kaisha Stable protein-containing preparation containing argininamide or valinamide
KR101968499B1 (ko) 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
JP6065591B2 (ja) 2011-08-04 2017-01-25 東レ株式会社 癌の治療及び／又は予防用医薬組成物
EP2740794B1 (en) 2011-08-04 2018-04-04 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
WO2013031237A1 (en) 2011-09-01 2013-03-07 Chugai Seiyaku Kabushiki Kaisha Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TWI593705B (zh) 2011-12-28 2017-08-01 Chugai Pharmaceutical Co Ltd Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
PT2824114T (pt) 2012-02-21 2019-08-05 Toray Industries Composição farmacêutica para o tratamento do cancro
ES2643241T3 (es) 2012-02-21 2017-11-21 Toray Industries, Inc. Composición medicinal para tratar y/o prevenir el cáncer
KR102005308B1 (ko) 2012-02-21 2019-07-30 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
PT2818482T (pt) 2012-02-21 2019-08-06 Toray Industries Composição farmacêutica para o tratamento de cancro
BR112014024209A2 (pt) 2012-03-30 2018-04-10 Toray Industries composição farmacêutica, agente farmacêutico e método de tratamento e/ou prevenção de cancêr da vesicula biliar
EP2832365B1 (en) 2012-03-30 2017-11-01 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of liver cancer
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
ES2668455T3 (es) 2012-09-28 2018-05-18 Chugai Seiyaku Kabushiki Kaisha Método para evaluar la reacción de coagulación sanguínea
BR112016001753B1 (pt) 2013-08-09 2023-10-03 Toray Industries, Inc Anticorpo, composição de anticorpo, composição farmacêutica, dna e uso de um anticorpo
RU2758952C1 (ru) 2013-09-27 2021-11-03 Чугаи Сейяку Кабусики Кайся Способ получения полипептидного гетеромультимера
KR102344170B1 (ko) 2013-12-27 2021-12-27 추가이 세이야쿠 가부시키가이샤 등전점이 낮은 항체의 정제방법
WO2015138411A1 (en) * 2014-03-10 2015-09-17 The Brigham And Women's Hospital, Inc. Anti-fibulin-3 antibodies and uses thereof
TW201625299A (zh) 2014-06-20 2016-07-16 Chugai Pharmaceutical Co Ltd 用於因第ｖｉｉｉ凝血因子及／或活化的第ｖｉｉｉ凝血因子的活性降低或欠缺而發病及／或進展的疾病之預防及／或治療之醫藥組成物
EP3185004A4 (en) 2014-08-20 2018-05-30 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016065245A1 (en) 2014-10-24 2016-04-28 Incept, Llc Extra luminal scaffold
CA2959821A1 (en) * 2014-10-24 2016-04-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance
SI3233921T1 (sl) 2014-12-19 2022-01-31 Chugai Seiyaku Kabushiki Kaisha Protitelesa proti C5 in postopki za uporabo
KR20240042169A (ko) 2014-12-19 2024-04-01 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
MX2017008978A (es) 2015-02-05 2017-10-25 Chugai Pharmaceutical Co Ltd Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos.
TW202339800A (zh) 2015-02-27 2023-10-16 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JP6698102B2 (ja) 2015-04-17 2020-05-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 凝固因子と多重特異的抗体を用いた併用療法
US10988543B2 (en) 2015-11-11 2021-04-27 Opi Vi—Ip Holdco Llc Humanized anti-tumor necrosis factor alpha receptor 2 (anti-TNFR2) antibodies and methods of use thereof to elicit an immune response against a tumor
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
JP7219005B2 (ja) 2015-12-28 2023-02-07 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
TW202342540A (zh) 2016-03-14 2023-11-01 日商中外製藥股份有限公司 用於癌之治療的細胞傷害誘導治療劑
BR112018069318A2 (pt) 2016-03-28 2019-01-22 Toray Industries composição farmacêutica para tratamento e/ou prevenção de um câncer, anticorpo ou fragmento do mesmo, combinação farmacêutica para tratamento e/ou prevenção de um câncer e método para tratar e/ou prevenir um câncer
EP3474854A4 (en) 2016-06-27 2020-02-19 The Regents of The University of California DRUG ASSOCIATIONS FOR THE TREATMENT OF CANCER
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
CR20190162A (es) 2016-09-06 2019-05-13 Hoffmann La Roche Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activado
BR112019008335A2 (pt) 2016-10-28 2020-01-28 Toray Industries conjugado de um anticorpo, composição farmacêutica e método para o tratamento e/ou a prevenção de um câncer
US20210107994A1 (en) 2017-03-31 2021-04-15 Public University Corporation Nara Medical University Medicinal composition usable for preventing and/or treating blood coagulation factor ix abnormality, comprising multispecific antigen binding molecule replacing function of blood coagulation factor viii
EP3617316A4 (en) 2017-04-27 2020-12-23 Chugai Seiyaku Kabushiki Kaisha COAGULATION FACTOR IX WITH IMPROVED PHARMACOKINETICS
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
TW201922796A (zh) * 2017-10-30 2019-06-16 國立研究開發法人國立癌症研究中心 可用於實體腫瘤治療之抗體及其抗體－藥物共軛物以及含其之抗癌劑
WO2019102435A1 (en) * 2017-11-27 2019-05-31 Euro-Celtique S.A. Humanized antibodies targeting human tissue factor
EP3735271A4 (en) 2018-01-04 2022-06-15 Iconic Therapeutics, Inc. ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS
CA3095719A1 (en) 2018-03-30 2019-10-03 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
KR20210010996A (ko) 2018-05-21 2021-01-29 추가이 세이야쿠 가부시키가이샤 유리 용기에 봉입된 동결건조 제제
CN115636142A (zh) 2018-05-28 2023-01-24 中外制药株式会社 填充喷嘴
CN114206444A (zh) 2019-04-18 2022-03-18 Ac免疫有限公司 用于治疗和诊断的新分子
MX2022006676A (es) 2019-12-04 2022-07-05 Ac Immune Sa Nuevas moleculas para terapia y diagnostico.
BR112022018166A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer
WO2021182573A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び／又は予防のための医薬品
EP4119160A4 (en) 2020-03-12 2024-04-03 Toray Industries, Inc. MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER
JPWO2021182570A1 (pt) 2020-03-12 2021-09-16
BR112022018171A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para o tratamento e/ou a prevenção de câncer, agentes aumentando a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
WO2021228218A1 (zh) 2020-05-14 2021-11-18 江苏恒瑞医药股份有限公司 抗cd25抗体、其抗原结合片段及其医药用途
EP4155405A4 (en) 2020-05-22 2024-07-03 Chugai Pharmaceutical Co Ltd ANTIBODY FOR NEUTRALIZING A SUBSTANCE HAVING SUBSTITUTION ACTIVITY FOR THE FUNCTION OF COAGULATION FACTOR VIII (F.VIII)
EP4229082A1 (en) 2020-10-16 2023-08-23 AC Immune SA Antibodies binding to alpha-synuclein for therapy and diagnosis
EP4263573A2 (en) 2020-12-18 2023-10-25 AC Immune SA Antibody delivery
JPWO2022270523A1 (pt) 2021-06-23 2022-12-29
JPWO2022270524A1 (pt) 2021-06-23 2022-12-29
CN117677398A (zh) 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
KR20240042415A (ko) 2021-07-27 2024-04-02 도레이 카부시키가이샤 암의 치료 및/또는 예방을 위한 의약품
EP4378476A1 (en) 2021-07-27 2024-06-05 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
AU2022338463A1 (en) 2021-09-03 2024-03-21 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
WO2023058705A1 (ja) 2021-10-08 2023-04-13 中外製薬株式会社 抗ｈｌａ－ｄｑ２．５抗体の製剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5223427A (en) * 1987-03-31 1993-06-29 The Scripps Research Institute Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
US5437864A (en) 1987-03-31 1995-08-01 The Scripps Research Institute Method of inhibiting blood coagulation in extracorporeal circulation by inhibiting human tissue factor
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
ES2134212T3 (es) 1991-04-25 1999-10-01 Chugai Pharmaceutical Co Ltd Anticuerpo humano reconstituido contra el receptor de la interleuquina 6 humano.
AU5093593A (en) 1992-08-28 1994-03-29 Scripps Research Institute, The Inhibition of tumor metastasis via neutralization of tissue factor function
US5648267A (en) 1992-11-13 1997-07-15 Idec Pharmaceuticals Corporation Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same
AU716282B2 (en) * 1995-06-07 2000-02-24 Johnson & Johnson Research Pty. Limited CDR-grafted anti-tissue factor antibodies and methods of use thereof

Also Published As

Publication number Publication date
EP1069185A1 (en) 2001-01-17
US7494647B2 (en) 2009-02-24
SK14812000A3 (sk) 2001-08-06
EP1069185B1 (en) 2011-06-08
CN1303431A (zh) 2001-07-11
ES2364266T3 (es) 2011-08-30
DK1069185T3 (da) 2011-06-27
EP2363484A3 (en) 2012-04-25
JP4180106B2 (ja) 2008-11-12
TR200101541T2 (tr) 2002-06-21
WO1999051743A1 (fr) 1999-10-14
BR9909382A (pt) 2000-12-05
AU752730B2 (en) 2002-09-26
US20040044187A1 (en) 2004-03-04
IL138801A0 (en) 2001-10-31
TR200002885T2 (tr) 2000-12-21
EP2363484A2 (en) 2011-09-07
AU3055699A (en) 1999-10-25
JP2008161198A (ja) 2008-07-17
US6677436B1 (en) 2004-01-13
NO20004946D0 (no) 2000-10-02
CA2325346A1 (en) 1999-10-14
PL343322A1 (en) 2001-08-13
KR20010042435A (ko) 2001-05-25
NO20004946L (no) 2000-12-04
EP1069185A4 (en) 2005-01-19
ATE512225T1 (de) 2011-06-15
JP3998419B2 (ja) 2007-10-24
HUP0101160A2 (hu) 2001-08-28

Similar Documents

Publication Publication Date Title
PL343322A1 (en) Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody
ZA978865B (en) Reshaped human anti-HM 1.24 antibody.
IL135221A0 (en) Natural humanized antibody and methods for the preparation thereof
EP0770628A4 (en) HUMAN ANTIBODIES RECONSTITUTED AGAINST HUMAN INTERLEUKIN-8
ATE283926T1 (de) Antikörper gegen die alpha-kette von humanem interleukin 5 rezeptor
HUT67945A (en) Parathyroid hormon and raloxifene for increasing bone mass
EP0198086A4 (en) MAN-MOUSE HYBRIDOMA PRODUCING HUMAN ANTIVIRAL ANTIBODY, PREPARATION METHOD AND HUMAN ANTIVIRAL MONOCLONAL ANTIBODY.
ZA921107B (en) Method of treating Type I diabetes.
IL117157A (en) Preparation of factor ix form biological sources
GR3029385T3 (en) Method of preparing a radioactive rhenium complex solution.
EP0281089A3 (en) Process for the preparation of factor viii:c deficient plasma, and deficient plasma obtained therwith
EP0922761A4 (en) MONOCLONAL ANTIBODY, SPECIFIC FOR ANTI-HUMAN FIBRINE MONOMER, METHOD FOR PRODUCING THE SAME, HYBRYDOM CELLS AND AN IMMUNOASSAY METHOD
EP0667395A4 (en) MONOCLONAL ANTIBODIES, APPLICATION AND PRODUCTION METHOD.
JPS57169471A (en) Guanidinopyrimidine